Inogen Announces Appointment of Chief Medical Officer

Inogen Announces Appointment of Chief Medical Officer

Dr. Stanislav Glezer to join as Executive Vice President and Chief Medical Officer Effective June 21, 2021 –

GOLETA, Calif.–(BUSINESS WIRE)–
Inogen, Inc. (NASDAQ: INGN), a medical technology company offering innovative respiratory products for use in the homecare setting, announced today that its Board of Directors has appointed Dr. Stanislav Glezer as Inogen’s Executive Vice President and Chief Medical Officer, effective June 21, 2021.

Nabil Shabshab, Inogen’s Chief Executive Officer, said, “On behalf of the Board of Directors, I would like to congratulate Stan on this appointment as I am confident that he will be a tremendous asset to Inogen and a great addition to our executive team. I believe that expanding our clinical expertise and evidence dossier in respiratory therapy will serve us well in our endeavors to drive our market development efforts to eventually increase the penetration of portable oxygen concentrators (POCs) in support of our growth strategy as well as help guide our innovation agenda. I believe Stan’s over 25 years of experience in clinical research and medical affair roles with strong experience in commercial, market access and other areas across a variety of medical technology and biotechnology firms will be a great enabler in building a stronger Inogen and elevating our clinical capabilities overall.”

“I am honored by the opportunity to lead the Medical Affairs, Clinical Research, [and Regulatory] organizations of Inogen in our mission to increase the freedom and independence for respiratory patients and to meaningfully improve clinical outcomes, as demonstrated by clinical evidence, generated in collaboration with health care practitioners and key opinion leaders in our effort to make our technologies the standard of care,” said Dr. Glezer. “I look forward to contributing to the next phase of Inogen’s planned growth as we continue to seek ways to design patient centric outcomes studies to improve access to our best-in-class product offerings, enable prescribers to better serve their patients and enhance our market position and value for our stockholders.”

Most recently, Dr. Glezer, 49, was with Becton, Dickinson and Company, a global medical technology company where he served as the Worldwide Vice President of Medical Affairs for Diabetes Care since September 2018 with Business Development responsibilities added under him since January 2021. Prior to joining Becton Dickinson, Dr. Glezer served as the Chief Medical Officer at Adocia S.A. a biotechnology company, from 2017 to 2018. From 2016 to 2017, Dr. Glezer served as Vice President of Global Medical Affairs at Novo Nordisk, Inc., a healthcare company. Earlier, Dr. Glezer served in a number of roles of progressively increasing seniority, including, Global Project Head for the largest late-stage pipeline asset, Vice President of Evidence and Value & Access, Vice President of Medical Affairs, and Senior Director of Medical Strategy & Operations, for Sanofi S.A., a multinational pharmaceutical company, from 2001 to 2015. Dr. Glezer holds a doctor of medicine from Moscow State University of Medicine and Dentistry and a MBA from California Coast University.

Inogen has used, and intends to continue to use, its Investor Relations website, http://investor.inogen.com/, as a means of disclosing material non-public information and for complying with its disclosure obligations under Regulation FD. For more information, visit http://investor.inogen.com/.

About Inogen

We are a medical technology company offering innovative respiratory products for use in the homecare setting. We primarily develop, manufacture and market innovative portable oxygen concentrators used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.

For more information, please visit www.inogen.com.

Cautionary Note About Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, among others, statements with respect to the announced management and organizational changes, statements concerning or implying Inogen’s future financial performance, trends and opportunities affecting Inogen, and the ability of management personnel to contribute to the development of and increasing patient access to Inogen’s products and technologies, expanding and growing its business, and increasing value for its stockholders. Forward-looking statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from currently anticipated results, including, but not limited to, risks related to its announced management and organizational changes, risks arising from the possibility that Inogen will not realize anticipated revenue; the risks related to the COVID-19 public health emergency; the impact of changes in reimbursement rates and reimbursement and regulatory policies; the possible loss of key employees, customers, or suppliers; risks relating to Inogen’s acquisition of New Aera and the integration of New Aera’s business and operations within those of Inogen; risks relating to reimbursement coding of the Tidal Assist© Ventilator (TAV); the possibility that Inogen will not realize anticipated revenue from the technology acquired from New Aera or that expenses and costs will exceed Inogen’s expectations; intellectual property risks if Inogen is unable to secure and maintain patent or other intellectual property protection for the intellectual property used in its products; and intellectual property risks relating to the acquisition of New Aera, including the risk of intellectual property litigation. In addition, Inogen’s business is subject to numerous additional risks and uncertainties, including, among others, risks relating to market acceptance of its products; competition; its sales, marketing and distribution capabilities; its planned sales, marketing, and research and development activities; interruptions or delays in the supply of components or materials for, or manufacturing of, its products; seasonal variations; unanticipated increases in costs or expenses; and risks associated with international operations. Information on these and additional risks, uncertainties, and other information affecting Inogen’s business and operating results are contained in Inogen’s Quarterly Report on Form 10-Q for the period ended March 31, 2021 and its subsequent SEC filings. These forward-looking statements speak only as of the date hereof. Inogen disclaims any obligation to update these forward-looking statements except as may be required by law.

Investor Relations and Media Contact:

Ali Bauerlein

[email protected]

KEYWORDS: California United States North America

INDUSTRY KEYWORDS: Managed Care Health Medical Devices

MEDIA:

Janus International to Participate in the Stifel 2021 Virtual Cross Sector Insight Conference

Janus International to Participate in the Stifel 2021 Virtual Cross Sector Insight Conference

TEMPLE, Ga.–(BUSINESS WIRE)–
Janus International Group, Inc. (NYSE:JBI) (“Janus” or the “Company”), a leading global manufacturer and supplier of turn-key building solutions and new access control technologies for the self-storage and other industrial sectors, announced today that members of Janus management will participate in the Stifel 2021 Virtual Cross Sector Insight Conference on Thursday, June 10, 2021.

ABOUT JANUS INTERNATIONAL

Janus International Group (“Janus”) is a leading global manufacturer and supplier of turn-key self-storage, commercial and industrial building solutions and new technologies, including: automation and access control technologies, roll up and swing doors, hallway systems, re-locatable storage units, and much more. The Janus team operates out of several U.S. locations and six locations internationally. More information is available at www.janusintl.com.

Investors

Rodny Nacier / Dan Scott

770-562-6399

[email protected]

Media

Phil Denning / Nora Flaherty

[email protected]

KEYWORDS: Georgia United States North America

INDUSTRY KEYWORDS: Engineering Manufacturing Commercial Building & Real Estate Construction & Property Building Systems Other Manufacturing

MEDIA:

Logo
Logo

Orion Group Holdings, Inc. Announces Sale of Tampa Property

Orion Group Holdings, Inc. Announces Sale of Tampa Property

HOUSTON–(BUSINESS WIRE)–
Orion Group Holdings, Inc. (NYSE: ORN) (“Orion” or the “Company”) a leading specialty construction company, today announced the sale of its Tampa property located on West Tyson Avenue.

Under its previously announced efforts to monetize certain real estate assets, Orion has completed the sale of its Tampa property on West Tyson Avenue and has received net proceeds of approximately $22 million. The Company will record a gain on the sale.

“The sale of the Tampa property further strengthens our balance sheet and enhances our liquidity as we are currently investing in our new ERP system, along with rebuilding and upgrading one of our dredges,” said Mark Stauffer, Orion’s President and Chief Executive Officer. “As we have previously stated, we will continue to evaluate all potential options for capital allocation as we execute our strategic plan.”

About Orion Group Holdings

Orion Group Holdings, Inc., a leading specialty construction company serving the infrastructure, industrial and building sectors, provides services both on and off the water in the continental United States, Alaska, Canada and the Caribbean Basin through its marine segment and its concrete segment. The Company’s marine segment provides construction and dredging services relating to marine transportation facility construction, marine pipeline construction, marine environmental structures, dredging of waterways, channels and ports, environmental dredging, design, and specialty services. Its concrete segment provides turnkey concrete construction services including pour and finish, dirt work, layout, forming, rebar, and mesh across the light commercial, structural and other associated business areas. The Company is headquartered in Houston, Texas with regional offices throughout its operating areas.

Forward-Looking Statements

The matters discussed in this press release may constitute or include projections or other forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, the provisions of which the Company is availing itself. Certain forward-looking statements can be identified by the use of forward-looking terminology, such as ‘believes’, ‘expects’, ‘may’, ‘will’, ‘could’, ‘should’, ‘seeks’, ‘approximately’, ‘intends’, ‘plans’, ‘estimates’, or ‘anticipates’, or the negative thereof or other comparable terminology, or by discussions of strategy, plans, objectives, intentions, estimates, forecasts, outlook, assumptions, or goals. In particular, statements regarding future operations or results, including those set forth in this press release and any other statement, express or implied, concerning future operating results or the future generation of or ability to generate revenues, income, net income, profit, EBITDA, EBITDA margin, or cash flow, including to service debt, and including any estimates, forecasts or assumptions regarding future revenues or revenue growth, are forward-looking statements. Forward looking statements also include estimated project start date, anticipated revenues, and contract options which may or may not be awarded in the future. Forward looking statements involve risks, including those associated with the Company’s fixed price contracts that impacts profits, unforeseen productivity delays that may alter the final profitability of the contract, cancellation of the contract by the customer for unforeseen reasons, delays or decreases in funding by the customer, levels and predictability of government funding or other governmental budgetary constraints and any potential contract options which may or may not be awarded in the future, and are the sole discretion of award by the customer. Past performance is not necessarily an indicator of future results. In light of these and other uncertainties, the inclusion of forward-looking statements in this press release should not be regarded as a representation by the Company that the Company’s plans, estimates, forecasts, goals, intentions, or objectives will be achieved or realized. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company assumes no obligation to update information contained in this press release whether as a result of new developments or otherwise.

Please refer to the Company’s Annual Report on Form 10-K, filed on March 2, 2021, which is available on its website at www.oriongroupholdingsinc.com or at the SEC’s website at www.sec.gov, for additional and more detailed discussion of risk factors that could cause actual results to differ materially from our current expectations, estimates or forecasts.

Orion Group Holdings Inc.

Francis Okoniewski, Vice President Investor Relations

(346) 616-4138

[email protected]

www.oriongroupholdingsinc.com

Robert Tabb, Executive Vice President & CFO

(713) 852-6500

www.oriongroupholdingsinc.com

KEYWORDS: Florida Texas United States North America

INDUSTRY KEYWORDS: Maritime Other Construction & Property Transport Manufacturing Commercial Building & Real Estate Construction & Property Other Manufacturing

MEDIA:

Logo
Logo

SeaSpine Announces Limited Commercial Launch of the WaveForm® L (Lateral) 3D-Printed Interbody System

CARLSBAD, Calif., June 08, 2021 (GLOBE NEWSWIRE) — SeaSpine Holdings Corporation (NASDAQ: SPNE), a global medical technology company focused on surgical solutions for the treatment of spinal disorders, today announced the limited commercial launch of its 3D-printed WaveForm L (Lateral) Interbody System. 

WaveForm L is designed for the LLIF (lateral lumbar interbody fusion) procedure, and seamlessly integrates with the entire Regatta NanoMetalene® lateral interbody portfolio, including the recently launched Regatta Lateral Plate. WaveForm L delivers a fully porous interbody solution with a graft aperture designed to accommodate a large amount of SeaSpine’s best-in-class allograft demineralized bone matrix offerings OsteoStrand® and OsteoStrand® Plus.

“The WaveForm L implant from SeaSpine is one of the best new lateral cages currently on the market,” said Douglas Orndorff, Orthopedic surgeon, Durango, CO. “It incorporates the new 3D-printed technology with amazing gyroid geometry and optimum pore size for fusion. In addition, it has a large internal hollow core that allows surgeons to place a large amount of orthobiologics material into the core. This design can allow for a considerable amount of bony fusion throughout the entire cage.”

The WaveForm L interbody offers the next level of 3D-printed architectural innovation, balancing key geometric and manufacturing advancements without compromising clinical requirements. WaveForm L utilizes innovative WaveForm technology to deliver a highly porous and robust interbody solution. This design is intended to balance subsidence resistance, implant stiffness, and orthobiologics packability, while maintaining radiographic visualization during intraoperative and postoperative imaging.

“WaveForm L is our fourth entry into the 3D-printed interbody space, with the launch of a fifth implant for ALIF (anterior lumbar interbody fusion) procedures planned in the coming months,” said Dennis Cirino, Senior Vice President of Global Spinal Systems. “This new lateral system is the accumulation of decades of experience in lateral interbody design and orthobiologics that captures significant efficiencies from sharing the same instrumentation with our existing Regatta system.  With an extensive ability to pack orthobiologics in and around its innovative graft aperture, Waveform L also maximizes endplate contact without compromising strength or radiolucency.  We are excited to continue building out our WaveForm portfolio as we expand our procedural footprint.”

About SeaSpine

SeaSpine (www.seaspine.com) is a global medical technology company focused on the design, development, and commercialization of surgical solutions for the treatment of patients suffering from spinal disorders. SeaSpine has a comprehensive portfolio of orthobiologics and spinal implants solutions, as well as a market leading surgical navigation system, to meet the varying combinations of products that neurosurgeons and orthopedic spine surgeons need to perform fusion procedures on the lumbar, thoracic, and cervical spine. SeaSpine’s orthobiologics products consist of a broad range of advanced and traditional bone graft substitutes that are designed to improve bone fusion rates following a wide range of orthopedic surgeries, including spine, hip, and extremities procedures. SeaSpine’s spinal implants portfolio consists of an extensive line of products to facilitate spinal fusion in degenerative, minimally invasive surgery (MIS), and complex spinal deformity procedures. Expertise in orthobiologic sciences, as well as spinal implants, software, and advanced optics product development, allows SeaSpine to offer its surgeon customers a differentiated portfolio and a complete solution to meet their fusion requirements. SeaSpine currently markets its products in the United States and in approximately 30 countries worldwide through a committed network of increasingly exclusive distribution partners.

Forward-Looking Statements

SeaSpine cautions you that statements included in this news release that are not a description of historical facts are forward-looking statements that are based on the Company’s current expectations and assumptions. Such forward-looking statements include, but are not limited to, statements relating to: the number of additional launches the Company plans this year in the 3D-printed interbody space; the design of WaveForm L and its ability to balance key geometric and manufacturing advancements without compromising clinical utility; and the ability of WaveForm technology to deliver a highly porous and robust interbody solution and appropriately balance subsidence resistance, implant stiffness, and orthobiologics packability, while maintaining radiographic visualization during intraoperative and postoperative imaging.. Among the factors that could cause or contribute to material differences between the Company’s actual results and the expectations indicated by the forward-looking statements are risks and uncertainties that include, but are not limited to: unexpected expense and delay, including as a result of developing and supporting the launch of new products, such as Waveform L, the fact that newly launched products may require substantial additional development activities, which could introduce further expense and delay, or as a result of delay in timely obtaining regulatory clearances; the ability of newly launched products, such as WaveForm L, to perform as designed and intended and to meet the needs of surgeons and patients, including as a result of the lack of substantial clinical validation of products following limited commercial (or “alpha”) launch; and other risks and uncertainties more fully described in the Company’s news releases and periodic filings with the Securities and Exchange Commission. The Company’s public filings with the Securities and Exchange Commission are available at www.sec.gov.

You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date when made. SeaSpine does not intend to revise or update any forward-looking statement set forth in this news release to reflect events or circumstances arising after the date hereof, except as may be required by law.

Investor Relations Contact

Leigh Salvo
(415) 937-5402
[email protected]



HRB Brands Announces Acquisition of Personal Care Brands from Helen of Troy

Iconic Brands Such as Brut®, Pert®, Sure®, Ammens®, Seabreeze® and Infusium® Added to Company’s Growing Portfolio

NEW YORK, June 08, 2021 (GLOBE NEWSWIRE) — HRB Brands LLC (“HRB” or the “Company”), a portfolio company of Tengram Capital Partners (“Tengram”), announced today that it has acquired a portfolio of personal care brands from Helen of Troy Limited (Nasdaq: HELE). The acquired portfolio includes 12 iconic and well-known brands such as Brut, Pert, Sure, Ammens, Seabreeze and Infusium.  

“Today’s acquisition complements, leverages, and builds upon the Company’s robust portfolio of personal care brands. These well-known, iconic brands have strong consumer loyalty across distribution channels in North and South America,” commented Tengram’s Managing Partner and Chairman of HRB Brands, William Sweedler.

“This strategic acquisition also brings with it a significant opportunity for international expansion, as the brands are currently sold in a number of countries and will drive growth across our combined platform. In addition, our management team has already begun development of renewed marketing and product innovation across the acquired portfolio that we will be sharing with our retail partners this Spring,” Jim Daniels, Chief Executive Officer of HRB Brands.

In conjunction with this transformative transaction, the Company has decided to rename the business to signify the transformation and evolution which includes significantly more brands in new categories along with international reach. The new name will be HRB Brands which stands for Healthy Responsible Beauty Brands.

The transaction was financed by White Oak and Wells Fargo along with transaction advisory services from Hilco Global.

About HRB Brands LLC

HRB Brands is one of the largest independent branded personal care companies in North America. HRB Brands holds leading market positions in the hair care and skin cleansing categories with iconic brands including ZEST®, VO5®, COAST®, Rave® SGX NYC®, THICKER FULLER HAIR®, Zero Frizz®, AND LA LOOKS®. HRB Brands is a portfolio company of Tengram Capital Partners.

About Tengram Capital Partners

Tengram Capital Partners is a private equity firm exclusively focused on investments in leading middle-market consumer companies that own strong recognizable brands. The team has a diverse background of consumer investing and operating expertise that assists and guides company management to unlock the true potential of their brands. Tengram invests in both traditional “growth” and “restructuring/turnaround” situations in each of the public and private sectors. Other Tengram investments, current and past, include Tommie Copper, Tone it Up, Algenist, Lime Crime Beauty, Revive, DevaCurl, NEST Fragrances, Robert Graham, Hudson Jeans, and El Cap.  Additional information can be found at: http://www.tengramcapital.com.

About Helen of Troy

Helen of Troy Limited (NASDAQ: HELE) is a leading global consumer products company offering creative solutions for its customers through a strong portfolio of well-recognized and widely-trusted brands, including OXO, Hydro Flask, Vicks, Braun, Honeywell, PUR, Hot Tools and Drybar. We sometimes refer to these brands as our Leadership Brands. All trademarks herein belong to Helen of Troy Limited (or its subsidiaries) and/or are used under license from their respective licensors.



Media Contact

Katherine Nash Goehring
(512) 757-2566
[email protected]

Pool Corporation To Present At The 44th Nasdaq Investor Conference

COVINGTON, La., June 08, 2021 (GLOBE NEWSWIRE) — Pool Corporation (Nasdaq:POOL) announced today that Mark W. Joslin, Senior Vice President and Chief Financial Officer, and Melanie Housey Hart, Vice President and Chief Accounting Officer, will be participating in investor meetings at the 44th Nasdaq Investor Conference on Tuesday, June 15, 2021, and Thursday, June 17, 2021. They will also be giving a virtual presentation on Thursday, June 17, 2021, at 8:30 AM Eastern Time.   Informational materials used during the conference will be posted on POOLCORP’s website on the morning of the conference.

Pool Corporation is the world’s largest wholesale distributor of swimming pool and related backyard products. POOLCORP operates approximately 400 sales centers in North America, Europe and Australia through which it distributes more than 200,000 national brand and private label products to roughly 120,000 wholesale customers. For more information about POOLCORP, please visit www.poolcorp.com.

CONTACT:

Curtis J. Scheel
Director of Investor Relations
985.801.5341
[email protected]



Helius Medical Technologies, Inc. to Participate in Noble Capital Markets’ Virtual Road Show Series

NEWTOWN, Pa., June 08, 2021 (GLOBE NEWSWIRE) — Helius Medical Technologies, Inc. (Nasdaq:HSDT) (TSX:HSM), (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today announced its participation in Noble Capital Markets’ Virtual Road Show Series, presented by Channelchek, which is scheduled for Thursday, June 10, 2021.

The event will feature a corporate presentation followed by a Q&A session proctored by Noble Capital Markets’ Senior Research Analyst, Joe Gomes, featuring questions submitted by the audience.

The live webcast of the event is scheduled for June 10, 2021, at 1:00 p.m. Eastern. Register for the webcast here. A recording will be available on Channelchek and under the ‘Events’ section of the Helius Medical Technologies investor relations website at https://heliusmedical.com/index.php/investor-relations/events/upcoming-events.

About Helius Medical Technologies, Inc.

Helius Medical Technologies is a neurotech company focused on neurological wellness. The Company’s purpose is to develop, license and acquire unique and non-invasive platform technologies that amplify the brain’s ability to heal itself. The Company’s first commercial product is the Portable Neuromodulation Stimulator (PoNSTM). For more information, visit www.heliusmedical.com.

About the PoNS

TM

Device and PoNS Treatment

TM

The Portable Neuromodulation Stimulator (PoNSTM) is an innovative non-surgical device, inclusive of a controller and mouthpiece, which delivers electrical stimulation to the surface of the tongue to provide treatment of gait deficit. The PoNS device is indicated for use in the United States as a short term treatment of gait deficit due to mild-to-moderate symptoms from multiple sclerosis (“MS”) and is to be used as an adjunct to a supervised therapeutic exercise program in patients 22 years of age and over by prescription only. It is authorized for sale in Canada as a class II, non-implantable, medical device intended as a short term treatment (14 weeks) of gait deficit due to mild and moderate symptoms from MS, and chronic balance deficit due to mild-to-moderate traumatic brain injury (“mmTBI”) and is to be used in conjunction with physical therapy. The PoNSTM is an investigational medical device in the European Union (“EU”) and Australia (“AUS”). It is currently under premarket review by the AUS Therapeutic Goods Administration.

Investor Relations Contact:

Westwicke Partners on behalf of Helius Medical Technologies, Inc.
Jack Powell, Vice President
[email protected]



LPL Financial to Present at the Virtual Morgan Stanley US Financials, Payments & CRE Conference

SAN DIEGO, June 08, 2021 (GLOBE NEWSWIRE) — LPL Financial LLC today announced that Chief Financial Officer Matt Audette will present at the virtual Morgan Stanley US Financials, Payments & CRE Conference on June 15.

The virtual presentation takes place at 2:00 p.m. ET. A live audio webcast of the presentation will be accessible at investor.lpl.com, with a replay available on the website beginning two hours after the presentation. The replay will remain available through July 6.


About LPL Financial


LPL Financial (Nasdaq: LPLA) was founded on the principle that the firm should work for the advisor, and not the other way around. Today, LPL is a leader* in the markets we serve, supporting more than 18,000 financial advisors, 800 institution-based investment programs and 450 independent RIA firms nationwide. We are steadfast in our commitment to the advisor-centered model and the belief that Americans deserve access to objective guidance from a financial advisor. At LPL, independence means that advisors have the freedom they deserve to choose the business model, services, and technology resources that allow them to run their perfect practice. And they have the freedom to manage their client relationships, because they know their clients best. Simply put, we take care of our advisors, so they can take care of their clients.

* Top RIA custodian (Cerulli Associates, 2019 U.S. RIA Marketplace Report)
No. 1 Independent Broker-Dealer in the U.S (Based on total revenues, Financial Planning magazine June 1996-2020)
No. 1 provider of third-party brokerage services to banks and credit unions (2020-2021 Kehrer Bielan Research & Consulting Annual TPM Report)

Securities and Advisory services offered through LPL Financial LLC, a registered investment advisor. Member FINRA/SIPC. We routinely disclose information that may be important to shareholders in the “Investor Relations” or “Press Releases” section of our website.

Investor Relations – Chris Koegel, (617) 897-4574
Media Relations – Lauren Hoyt-Williams, (980) 321-1232
investor.lpl.com/contactus.cfm



SI-BONE to Present at the 2021 JMP Securities Life Sciences Conference

SANTA CLARA, Calif., June 08, 2021 (GLOBE NEWSWIRE) — SI-BONE, Inc. (Nasdaq: SIBN), a medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, today announced that the company will be participating in the upcoming 2021 JMP Securities Life Sciences Conference. Management is scheduled to present on Thursday, June 17 at 2:30 p.m. Eastern Time / 11:30 a.m. Pacific Time.

Interested parties may access a live and archived webcast of the presentation on the “Investors” section of the company’s website at: www.si-bone.com

About SI-BONE, Inc.
SI-BONE is a medical device company that pioneered minimally invasive surgery of the SI joint with the iFuse Implant System. Studies have shown that the SI joint can be a source of pain in 15% to 30% of chronic low back pain. The iFuse Implant™, commercially available since 2009, is the only SI joint fusion device supported by multiple prospective clinical studies, including two randomized controlled trials, showing improved pain, patient function and quality of life resulting from treatment. There are over 90 peer-reviewed publications demonstrating the safety, durable effectiveness, and biomechanical and economic benefits unique to the iFuse Implant (www.si-bone.com/results). This body of evidence has enabled multiple government and private insurance payors to establish coverage of the SI joint fusion procedure exclusively when performed with the iFuse Implant System.

The iFuse Implant System is intended for sacroiliac fusion for conditions including sacroiliac joint dysfunction that is a direct result of sacroiliac joint disruption and degenerative sacroiliitis. This includes conditions whose symptoms began during pregnancy or in the peripartum period and have persisted postpartum for more than 6 months. The iFuse Implant System is also intended for sacroiliac fusion to augment stabilization and immobilization of the sacroiliac joint in skeletally mature patients undergoing sacropelvic fixation as part of a lumbar or thoracolumbar fusion. In addition, the iFuse Implant System is intended for sacroiliac fusion in acute, non-acute, and non-traumatic fractures involving the sacroiliac joint. There are potential risks associated with the iFuse Implant System. It may not be appropriate for all patients and all patients may not benefit.

SI-BONE and iFuse Implant System are registered trademarks of SI-BONE, Inc. ©2021 SI-BONE, Inc. All Rights Reserved. 06082021

Investor Contact:

Matt Bacso, CFA
[email protected]

Media Contact:

Joe Powers
[email protected]



Stratus Properties Inc. Announces The Saint June, a Luxury Multi-Family Development in Barton Creek

Stratus Properties Inc. Announces The Saint June, a Luxury Multi-Family Development in Barton Creek

Project to Feature 182 Units with a Focus on Design Sustainability

Construction Financing in Place

AUSTIN, Texas–(BUSINESS WIRE)–
Stratus Properties Inc. (NASDAQ: STRS) (“Stratus” or the “Company”) today announced its plans and construction financing for The Saint June, a 182-unit luxury garden style multi-family development within the Amarra subdivision of the Barton Creek community. The Saint June will be built on approximately 36 acres and will be comprised of multiple buildings featuring one, two and three bedroom apartments for lease with exceptional amenities, including a resort style clubhouse, fitness center, pool and extensive green space.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210608006071/en/

Rendering of The Saint June (Photo: Business Wire)

Rendering of The Saint June (Photo: Business Wire)

William H. Armstrong III, Chairman and Chief Executive Officer, stated, “Our projects within the beautiful Barton Creek community focus on using sustainable design features, materials, and construction techniques to ensure we protect the natural setting. Similar to the recently announced Holden Hills project, The Saint June is designed to complement the hill country environment with a focus on sustainable luxury and will be another unique, high-quality property that is key to our successful strategy of developing and monetizing properties. This multi-family development project will offer apartments for lease, which will add value to our leasing segment operations in the long-term. The Saint June is the most recent addition to our growing pipeline of projects focused on sustainability, and is located minutes away from downtown Austin, offering tenants easy access to restaurants, shops and entertainment.”

The project will be owned by The Saint June, L.P., a Texas limited partnership. Project financing is in place and includes a construction loan to the limited partnership in the amount of approximately $30.3 million, guaranteed by Stratus, to finance approximately 55 percent of the estimated approximately $55 million project costs. The remaining estimated project costs will be funded by equity contributed to the limited partnership by Stratus and a new unrelated private equity investor. Stratus will receive 34.13 percent of the limited partnership’s equity in exchange for its contribution of the land, development costs to date and cash, and will manage the project.

Stratus expects to begin project construction before the end of the second quarter of 2021, subject to receiving a final county permit. First resident move-ins are planned for late 2022.

About Stratus Properties Inc.

Stratus is a diversified real estate company engaged primarily in the acquisition, entitlement, development, management, and sale of commercial, and multi-family and single-family residential real estate properties, real estate leasing, and the operation of hotel and entertainment businesses located in the Austin, Texas area and other select, fast-growing markets in Texas.

Forward-Looking Statements

This press release contains forward-looking statements in which Stratus discusses factors it believes may affect its future performance. Forward-looking statements are all statements other than statements of historical fact. The words “anticipates,” “may,” “can,” “could,” “plans,” “believes,” “potential,” “possible,” “estimates,” “expects,” “projects,” “targets,” “intends,” “likely,” “will,” “should,” “to be” and any similar expressions are intended to identify those assertions as forward-looking statements. Stratus cautions readers that forward-looking statements are not guarantees of future performance, and its actual results may differ materially from those anticipated, expected, projected or assumed in the forward- looking statements. Important factors that can cause Stratus’ actual results to differ materially from those anticipated in the forward-looking statements include, but are not limited to, Stratus’ ability to obtain final permits for and close the financing arrangements for the development of The Saint June and execute profitably on its development plan for The Saint June, Stratus’ ability to continue to effectively develop and execute its strategies, including its ability to develop, finance, construct and sell properties on its anticipated schedule and at prices its Board considers acceptable, Stratus’ ability to obtain various entitlements and permits, a decrease in the demand for real estate in select markets in Texas where Stratus operates, changes in economic, market and business conditions, the uncertain and ongoing impact of the COVID-19 pandemic, and other factors described in more detail under the heading “Risk Factors” in Stratus’ Annual Report on Form 10-K for the year ended December 31, 2020, filed with the U.S. Securities and Exchange Commission.

Investors are cautioned that many of the assumptions upon which Stratus’ forward-looking statements are based are likely to change after the forward-looking statements are made. Further, Stratus may make changes to its business plans that could affect its results. Stratus cautions investors that it does not intend to update its forward-looking statements more frequently than quarterly notwithstanding any changes in its assumptions, business plans, actual experience, or other changes, and Stratus undertakes no obligation to update any forward-looking statements.

A copy of this release is available on Stratus’ website, stratusproperties.com.

Financial and Media Contact:

William H. Armstrong III

(512) 478-5788

KEYWORDS: United States North America Texas

INDUSTRY KEYWORDS: Entertainment General Entertainment Residential Building & Real Estate Commercial Building & Real Estate Construction & Property REIT

MEDIA:

Photo
Photo
Rendering of The Saint June (Photo: Business Wire)